Amgen Inc. · AMGN · FY2026 Q1 · Calendar Q2 2026

Amgen Beats Q1 Estimates, Raises 2026 Guidance as Growth Drivers Deliver

Amgen's Q1 2026 reflects a multi-product growth strategy gaining traction — six growth drivers now account for 70% of revenue, and management raised full-year guidance on both revenue and EPS. The EPS beat was more pronounced than the modest revenue beat, suggesting improving operating leverage. Raised guidance to $37.1–$38.5 billion revenue and $21.70–$23.10 EPS signals confidence in sustained momentum through 2026. Pipeline highlights include Meritide switch studies testing extended dosing intervals (8- and 12-week) that could differentiate Amgen in a crowded obesity market, and Imdeltra's advancement into frontline small-cell lung cancer settings through an FDA real-time trial pilot. Counterbalancing these positives, patent expirations and biosimilar erosion — particularly for Prolia/XGEVA — remain a structural overhang, and the stock's roughly 5% decline on the report suggests…

Reported After market closeNASDAQHealthcare $203.07B market cap
90quality score

Company context

Snapshot as of publication

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.…

Earnings scorecard

Reported versus consensus
Reported EPS $5.15 Consensus $5
EPS surprise +8.0% Reported versus consensus
Reported revenue $8.62B Consensus $8.58B
Revenue surprise +0.5% Reported versus consensus

Market reaction

event-close to next-session close
Stock move -4.7% Event window
SPY move +0.3% Same window
Abnormal move -5.0% Stock minus SPY
Volume 1.6× Versus trailing sessions
Subsequent drift -0.2% Up to 20 sessions
AMGNSPY benchmark

Follow AMGN with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Q1 2026 product sales grew 4% year over year, with six growth drivers — Repatha, Evenity, Imdeltra, TEPEZZA, and others — contributing 70% of total revenue. Management raised full-year 2026 revenue guidance to $37.1–$38.5 billion and EPS to $21.70–$23.10. Capex is planned at $2.6 billion for the year, an increase reflecting manufacturing scale-up for upcoming launches. On the pipeline front, Meritide Phase III switch studies will evaluate 8-week and 12-week dosing versus weekly GLP-1 injectables, Imdeltra advanced into frontline and maintenance settings for small-cell lung cancer, and AI-driven manufacturing automation reduced line clearance time from approximately 30 minutes to roughly 2 minutes per batch.

Guidance delta

Management raised its full-year 2026 outlook: revenue to $37.1–$38.5 billion and EPS to $21.70–$23.10. Guidance sentiment was characterized as raised and management tone as confident. Capex is set at $2.6 billion, up from prior levels, reflecting investment in manufacturing capacity for forthcoming product launches. Prior-quarter guidance figures were not available for direct comparison.

Key takeaways

  • Q1 sales grew 4% with six growth drivers delivering 70% of total revenue.
  • Repatha continues strong growth, with additional primary-prevention market opportunity following guideline updates.
  • Meritide shows promising less-frequent dosing (8- and 12-week intervals) and improved GI tolerability in early studies.
  • Imdeltra is now standard of care in second-line small-cell lung cancer and advancing into frontline indications.
  • Full-year 2026 guidance raised: revenue to $37.1–$38.5 billion, EPS to $21.70–$23.10, with $2.6 billion capex planned.

Management priorities

  • Seek regulatory approval for Meritide with launch planned for later in 2026.
  • Global rollout of TEPEZZA following the Japan launch.
  • Advance Imdeltra into frontline and maintenance settings for small-cell lung cancer.
  • Scale AI-enabled drug discovery and manufacturing across the enterprise.
  • Expand Amgen Now cash-pay access model and evaluate international opportunities.

Related earnings events

Healthcare
TMO · FY2026 Q2 · Calendar Q3 2026TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises AgainUNH · FY2026 Q2 · Calendar Q3 2026UNH Q2 2026: EPS Beat, Guidance Raised as AI and Cost Trends ImproveJNJ · FY2026 Q2 · Calendar Q3 2026JNJ Q2 2026: $25.3B Sales, Guidance Raised to $101.1B Midpoint, New Launches Drive Growth

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T13:11:06.734976+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T13:11:06.732148+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.